Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan

Endocrine Journal

Volumn 59, Issue 3, 2012, Pages 197-204

  Tajiri, Yuji ^a   Tsuruta, Munehisa ^a   Ohki, Tsuyoshi ^a   Kato, Tomoko ^a   Sasaki, Yuko ^b   Tanaka, Kayo ^c   Kono, Shusuke ^d   Tojikubo, Masayuki ^e   Yamada, Kentaro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Chikugo City Hospital   (Japan)

^c Ohmuta City Hospital   (Japan)

^d Hirai Clinic   (Japan)

^e SHIN KOGA HOSPITAL   (Japan)

Author keywords

Dipeptidyl peptidase IV (DPP IV) inhibitor; Life style; Oral hypoglycemic agent; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN;

ADULT; AGE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; DIABETIC PATIENT; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GENDER; HUMAN; JAPAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PATIENT CODING; RELAPSE; SCORING SYSTEM; WEIGHT CHANGE; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIFE STYLE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84859097891     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0248     Document Type: Article

References (17)

1. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596.
2. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835.
3. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89: 2078-2084.
4. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM (1998) Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68: 525-530.
5. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
6. Miller S, St Onge EL (2006) Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 40: 1336-1343.
7. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM (2010) Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 12: 613-622.
8. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Arjona Ferreira JC (2011) Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int 2: 32-44.
9. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K (2010) Report of the Committee on the classifi{ligature}cation and diagnostic criteria of diabetes mellitus. The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int 1: 2-20.
10. Fujii H, Muto T, Haruyama Y, Nakade M, Kobayashi E, Ishisaki K, Yamasaki A (2010) Community-based lifestyle modification of cardiovascular disease risks in middle-aged Japanese: a 27-month update. Tohoku J Exp Med 220: 307-318.
11. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742.
12. Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, Yoo JS, Nam JS, Cho MH, Park JS, Ahn CW, Kim KR (2011) Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus. Diabetes Metab J 35: 159-165.
13. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ, Sitagliptin Study 049 Group (2010) Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 12: 252-261.
14. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4: 329-335.
15. Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y (2010) Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57: 667-672.
16. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150-156.
17. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203.